Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
June 14, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET
|
Mineralys Therapeutics, Inc.
– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 – – Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment...
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
May 06, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
May 02, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 21, 2024 07:00 ET
|
Mineralys Therapeutics, Inc.
– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025 – –...
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024
March 13, 2024 16:05 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension,...
Mineralys Therapeutics Announces $120 Million Private Placement Financing
February 08, 2024 08:00 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
January 29, 2024 16:05 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
January 04, 2024 16:05 ET
|
Mineralys Therapeutics, Inc.
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic...